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The vast majority of paediatric HIV occurs in sub-Saharan Africa and could be averted 
through implementation of effective Prevention of Mother to Child Transmission (PMTCT) 
strategies. At the United Nations General Assembly Special Session on HIV/AIDS in 2001, 
members committed themselves to the goal of reducing paediatric HIV by 20% by 2005 
and by 50% by 2010. In South Africa, rates of HIV infection range between 28% in 
KwaZulu-Natal and 16% in the Western Cape. The South African National Department of 
Health has, over the past few years, phased in a comprehensive package for PMTCT of 
HIV. KwaZulu-Natal implemented its programme in 2002. The South African private 
healthcare sector follows guidelines of those of developed countries for PMTCT. Not much 
data is available of the outcome of infants born to HIV positive mothers managed in private 
practice. In view of this, the present study aimed to assess success or otherwise of PMTCT 
in private paediatric practice in South Africa.
 
 
Eight of the 20 private paediatricians, in the central region of Ethekweni Metro of 
KwaZulu-Natal (Durban Central Area), agreed to participate in a retrospective study. Data 
for all their HIV exposed infants between January 2004 and June 2005 were reviewed. One 
hundred and one Black African infants were born to 100 HIV positive women aged 29.85 
years (SD 5.38; range 18-44 years). The median CD4 count was 426 (IQR 244-613). The 
median viral load at first presentation was 3.97 logs (IQR 1.6-5.8) or 11 391 copies/ml 
(IQR 2 013-41 502). Eighty six women had HAART, nine had other antiretroviral therapy 
and five had no prophylaxis. Treatment started before 34 weeks in 72 women. There were 
93 caesarean sections. 
 
There were 20 low birth weight neonates, 18 were preterm and all had been formula fed 
and received AZT for six weeks. Of the 92 tested, two (one preterm) were positive. 
Although caesarean deliveries, both these mothers had not adhered to the optimal treatment 
protocol. Of the rest, eight did not return for HIV testing and one died (the only neonatal 
death). This death was unlikely to have been HIV related. The transmission rate of less 
than one percent in those women who followed the protocol optimally is much better than 
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ACRONYMS AND ABBREVIATIONS 
 
AfA  Aid for AIDS 
AGA  Appropriate for gestational age 
AIDS  Acquired immunodeficiency syndrome 
ANC  Antenatal clinic 
ART  Antiretroviral therapy 
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CDC  Centres for Disease Control and Prevention 
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HAART Highly active anti retroviral therapy 
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IQR  Interquartile range 
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KZN  KwaZulu-Natal  
MDGs  Millennium Development Goals   
MTCT  Mother to Child transmission of HIV 
NVP  Nevirapine 
PCP  Pneumocystis jirovecii pneumonia   
PCR  Polymerase Chain Reaction  
PIH  Pregnancy induced Hypertension 
PMTCT Prevention of mother to child transmission  
sdNVP  Single dose Nevirapine  
3TC  Lamivudine  
UNAIDS Joint United Nations Programme on HIV/AIDS  
UNGASS United Nations General Assembly Special Session 
UK  United Kingdom 
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Since the beginning of the HIV/AIDS epidemic, almost two and a half decades ago, it 
continues to take its devastating toll, wreaking havoc as it continues to march 
unrelentingly. During 2007 alone, 33 million people were living with HIV/AIDS.
1 
Sub-
Saharan Africa is worst hit by this catastrophe where a quarter of a million people are 
living with HIV/AIDS.
2
 Every day a staggering six thousand people die in Africa of AIDS 
and its related complications. Sadly, last year 2.7 million people had become newly 
infected with HIV. Its social and economic consequences are widely felt, in all sectors of 
society such as health, education, industry, agriculture, transport, human resources and the 
economy. In Africa, HIV/AIDS is not just a health issue. It poses a barrier to development, 




Almost 40% of the population in Botswana and Swaziland are living with HIV/AIDS. 
South Africa with its estimated 5.7 million people living with HIV has the largest number 
of infections in the world. Estimates suggest 18.1% of adults (15-49 years) were living with 
HIV in 2007, 3.1 million of them women.
2
 Unfortunately there is no sign yet of a decline in 
the epidemic. More than half (55%) of all South Africans infected with HIV live in the 
KwaZulu-Natal (KZN) and Gauteng provinces. KZN has consistently reported the highest 
HIV prevalence in the country. The national HIV prevalence estimate stands at 28.0% 
(CI:26.9%-29.1%). HIV prevalence among pregnant women in the various provinces is as 





Children are the innocent victims of this deadly epidemic. Last year, just over a quarter of a 
million children died of HIV/AIDS. Currently there are 2 million children infected with 
HIV in the world. In more than nine times out of ten, children become infected with HIV 
through mother to child transmission (MTCT). The tragedy is that although we presently 
have the knowledge and the means of preventive measures, to cut down drastically on this 
terrible situation, yet the figures continue to rise.
4  
 3 
The vast majority of paediatric HIV occurs in sub-Saharan Africa and could be largely 
averted through effective use of MTCT prevention strategies. HIV-infected newborns are 
becoming uncommon in the USA and Europe.
1
 At the United Nations General Assembly 
Special Session (UNGASS) on HIV/AIDS in 2001, member states committed themselves 




The achievement of three of the Millennium Development Goals (MDGs) to be met by 
2015 is directly linked to reducing vertical transmission of HIV as follows:  
- 4
th
 MDG: Reduce by two thirds the mortality rate among children under five. 
- 5
th
 MDG: Reduce by three quarters the maternal mortality ratio. 
- 6
th
 MDG: Halt and begin to reverse the spread of HIV/AIDS.
6 
 
HIV transmission from infected mother to the infants takes place in utero, intrapartum, and 
postnatally through breastfeeding. The in utero rate is 5-10%, intrapartum rate is 10-20%, 
and the postnatal (breastfeeding) rates vary according to the duration of breastfeeding. In 
the absence of any preventative strategy there is a 30-45% possibility of overall vertical 




The risk of MTCT is affected by a number of factors, maternal, foetal, viral and 
behavioural. The main maternal factors are advanced disease, high viral load, and HIV 
infection acquired during pregnancy or breastfeeding and sexually transmitted disease. The 
obstetric factors are vaginal delivery as opposed to caesarean, prolonged rupture of 
membranes, invasive procedures and episiotomy. The infant factors are prematurity, 
breastfeeding and lesions of skin and/or mucous membranes.
7 
 
Prevention of Mother to Child Transmission (PMTCT) of HIV encompasses the following 
aspects:
 
 Primary prevention of HIV infection among parents to be. 
 Prevention of unwanted pregnancies. A cost-effectiveness study of PMTCT in eight 
African countries demonstrated that lowering HIV prevalence among women by 
 4 
1.25% or reducing unintended pregnancies among HIV-infected women by 16%, 
yielded an equivalent reduction in HIV-infected infant transmissions to that 
achieved by PMTCT using single-dose nevirapine (sdNVP).
4
  
 Prevention of viral transmission from mother to child as part of routine antenatal 
care. This PMTCT is achieved by various approaches: antiretroviral prophylaxis for 
the mother, prophylaxis to the infants, implementation of safe delivery practices, 
and use of safe alternatives to breastfeeding. 
 The provision of treatment, care and support occurs not only for the HIV-infected 
mother but should include their infants and family. This must be fully integrated 
into ongoing efforts to improve maternal and child health services, and be tailored 
to the needs of women for safe and effective antenatal, obstetric and reproductive 
health services. 
 
1.2 Prevention Trials  
 
1.2.1 Developed Countries  
 
In 1994, administration of zidovudine (AZT) to the mother during pregnancy and labour, 
and to the infants was shown to reduce perinatal transmission.
8,9 
The AZT regimen started 
from 14 to 34 weeks and it included antepartum AZT (100 mg
 
orally five times daily), 
intrapartum AZT (2 mg/kg given intravenously over a one-hour period, then
 
1 mg/kg per 
hour until delivery), and AZT for
 
the newborn (2 mg/kg orally every six hours for six
 
weeks). A regimen consisting of AZT given antepartum
 
and intrapartum to the mother and 
to the newborn for six weeks
 
reduced the risk of MTCT HIV transmission by 
approximately
 





Incorporation of this regimen into clinical practice in the USA and other more developed 
countries, and avoidance of breastfeeding, resulted in falling perinatal transmission rates to 
as low as 2-4%. Further decrease in transmission rates of 2% or less had been reported 
when AZT was combined with elective caesarean delivery or when women were treated 
 5 
with combination antiretroviral (ARV) regimens that reduce maternal viral load to 
undetectable levels.11 
 
The Women and Infants Transmission Study demonstrated that very low rates of vertical 
transmission were achievable with the use of highly active antiretroviral therapy (HAART). 
The protective effect of therapy increased with the complexity and duration of the 
regimen.
12 
The more recent European Collaborative Study added that caesarean section 
delivery to all HIV-infected women, even in areas where HAART is available, is 
appropriate clinical management, especially for persons with detectable viral loads.
13
 
Some of the developed countries have reached a stage where elimination of paediatric HIV 
can be contemplated. For example, in Sweden vertical transmission fell from 24.7% in 
1985-1993 to 5.7% in 1994-1998 and 0.6% in 1999-2003.
14 
PMTCT uptake increased from 
2.3% to 91.6% during the same period, and the elective caesarean delivery rate increased 
from 8.0% to 80.3%. No vertical transmission of HIV occurred in Sweden after 1999. 
 
1.2.2 Developing countries 
 
In less developed countries the situation is vastly different. The above regimens were far 
too expensive at that time. The complex nature of their usage was also a barrier for the 
majority of the public. Trials over the past decade have now proven the efficacy of several 
ARV interventions. Several simpler, more affordable short ARV regimens have been 
shown to decrease vertical transmission in less resourced countries, with reduced but 
persistent efficacy in breastfeeding populations.
4 
Studies in Thailand among non-
breastfeeding populations and in Africa among breastfeeding populations informed the 
decisions for ARV usage in the developing countries. 
 
Among non-breastfeeding women the short course CDC Thai regimen using AZT from 
week 36 of pregnancy through labour and delivery, reduced transmission to 9.4% at six 
months with a 50.1% absolute reduction.
15
 Other studies also using AZT, compared 
different duration of AZT given to the women and infants. These studies suggested that in 
utero transmission was significantly higher with shorter maternal treatment (5.1%) than 
 6 
with longer maternal treatment (1.6%) and, although beneficial, longer duration of 




Lallemant et al. used AZT from 28 weeks of pregnancy and combined this with sdNVP 
given to either the women during labour and delivery or to the newborn. The transmission 
rate at 6 months was as low as 1.1%.
17
 Mandelbrot et al. using combination ARVs, AZT 
and lamivudine (3TC) reduced transmission to 1.6%.
18
 In Thailand, a study starting AZT a 




The Petra study was a randomised, double-blind, placebo-controlled trial that examined the 
efficacy of three short-course regimens of AZT and 3TC in Tanzania, South Africa, and 





The South African Intrapartum Nevirapine Trial (SAINT) study had a successful outcome. 
It used a simple, inexpensive regimen of NVP, given at the onset of labour, and 




The landmark HIVNET 012 study in 1999 established that a short intrapartum and neonatal 
regimen of sdNVP to the mother at onset of labour, and to the infants within 72 hours of 
birth, reduced the risk of perinatal HIV transmission among breastfeeding women in 
Uganda by 47% at 14-16 weeks and by 41% at 18 months compared to a short 
intrapartum/neonatal regimen of AZT.
22, 23 
This trial was hailed as a boon to most of the 
affected countries in the third world because of simplicity, safety, affordability and 
effectiveness of the regimen.  
 
However, subsequent problems arise in that the regimen renders the women or infants more 
susceptible to the development of NVP resistant strains of HIV. Factors found to relate to 
the development of resistance are: NVP’s long half-life, high maternal viral load, low CD4  
 7 
counts, HIV subtype (Clade C>A>D), more maternal doses of NVP with shorter intervals 




Trials which have continued using combination ARVS, after the above studies had been 
done, showed improved efficacies. It has been reported that in West Africa, a combination 
of AZT from 36 weeks and sdNVP obtained a transmission rate of 6.5% at 4-6 weeks, and 
4.7% with the addition of 3TC from 36 weeks. With AZT alone the transmission was 
14.7% at 4-6 weeks.
4, 8 
 
In summary, shorter courses of ARVs do reduce perinatal MTCT and are appropriate for 
developing countries. However, longer ARV prophylaxis (from about 28 weeks) through 
labour and delivery, and into the postpartum period, is more effective than shorter 
antepartum courses. Combination ARVs improved outcome over single ARVs. 
 
As reported by Coovadia, a 2004 review of PMTCT trials in developing countries by the 
Ghent Group concluded that the most frequently used ARVs were AZT, AZT and 3TC, and 




Because of its simplicity and efficacy, sdNVP was initially adopted as the standard of care 
in resource-limited countries worldwide and had been endorsed by UNAIDS and many 
other international health organizations. NVP still has a role in PMTCT programmes in 




Many less developed countries are having difficulty in implementing even these simpler 
regimens. Challenges include inadequate basic maternal child healthcare infrastructure, 
lack of prenatal HIV counselling and testing programmes, attitudes of healthcare workers 
and severely limited resources. 
 
The World Health Organization (WHO) first issued recommendations for the use of ARV 
drugs for PMTCT in 2000. In 2006, the guidelines were updated to incorporate new 
evidence and were aligned with the global commitment to universal access; integration of 
 8 
PMTCT into general health care delivery, the use of highly effective regimens to reduce 





The criteria for commencing pregnant women on ARV treatment recommends that women 
in stage 3, or with a CD4 count of 350, should be initiated on ARV treatment. A 
prophylactic regimen that includes maternal AZT (from 28 weeks of pregnancy or as soon 
as possible thereafter) plus sdNVP, and a 7-day tail of AZT and 3TC is recommended. The 
infant regimen includes a one-week course of AZT.
 
 
1.3 PMTCT in South Africa 
 
 
1.3.1 The Public Healthcare Sector 
 
South Africa has an estimated one million deliveries annually. Working on an average 25% 
HIV prevalence rate, this translates to almost a quarter of a million HIV positive pregnant 
women.
3,7
 South Africa has considerably more resources than other sub-Saharan countries, 
but the government has been extremely resistant to implementing a programme to prevent 
MTCT of HIV.  
 
In the early 2000s the country had been shrouded in a veil of controversy sparked by ex 
President Thabo Mbeki's flirtation with the denialist view that HIV might not cause AIDS, 
and that AIDS medications were toxic and inviting foreign AIDS denialist to advise his 
government.
26 
Although the successful outcome of the SAINT study had been supported by 
the drug manufacturer's offer of free NVP for the PMTCT in developing countries there 
was a delay in implementation of such policy in South Africa. AIDS experts criticized the 
health ministry for this delay. The Treatment Action Campaign, a non governmental AIDS 
activist group, confronted the South African government in court in 2002 for not making 
MTCT prevention available to pregnant women.
27
 It won this case on the basis of the South 
African constitutional guarantee of the right to health care, and the government was 
ordered to provide MTCT programs in public clinics. 
 9 
 
South African National Department of Health has, over the past few years, phased in a 
comprehensive package for PMTCT. KZN implemented its programme in 2002. The main 
regimen used for PMTCT in the public sector had been sdNVP which is given during 
labour and a single dose to the baby within 72 hours of birth. Recently, the Department of 
Health
 
revised its PMTCT guidelines to dual therapy as follows: AZT is given to the 
women from 28 weeks and sdNVP and AZT is administered at onset of labour. The infants 
are offered sdNVP and AZT for 7 days. If the maternal CD4 < 200 or there is suboptimal 
maternal ARV then the infant gets AZT for 1 month in addition to the sdNVP. If the 
maternal CD4 < 200 then HAART is initiated for her treatment.
28 
 
A few studies have described the operational effectiveness of PMTCT programmes in 
South Africa. The 2002 evaluation of South Africa’s PMTCT of HIV reported that of 50% 
of HIV exposed infants followed up, 18% tested positive for HIV.
29 In Johannesburg a 
lower vertical transmission rate of 8.7% was reported in 2002.
30
 A study in KZN in 2006 





The Western Cape, which implemented the dual drug therapy of short-course AZT and 
sdNVP, reported a MTCT rate of 8.8% in 2003.
32, 33 
Thus far the most promising reduction 
in vertical transmission to 2.9% has come from the McCord PMTCT programme, a 
smaller, non-governmental project in KZN.
34
 Some 44% of these women had had low 
enough CD4 cell counts to receive HAART while pregnant. Ninety eight percent of the 




1.3.2 The Private Healthcare Sector  
 
South Africa spends a relatively large amount (8.4%) of its gross domestic product (GDP) 
on healthcare, compared to other developing countries.
35
 In South Africa, around 61.4% of 
health expenditure occurs in the private sector which caters for a minority of the 
population. In May 2006, the General Household Survey, conducted by Statistics SA, 
revealed that 96% of people who obtain health services in the private sector are satisfied as 
opposed to 82% in the public sector.  
 
The greater per capita expenditure in the private sector results in better standards of care, 
more sophisticated methods of management and more luxurious facilities than in the public 
sector.
36
 The private healthcare industry has also increasingly become the main driver of 
innovation in healthcare. One such example is the Aid for AIDS (AfA) programme which 
very ably demonstrated the very early response to the HIV epidemic. This programme has 




AfA is a private sector disease management programme, available to beneficiaries and 
employees of contracted medical funds and companies in Africa, who are living with 
HIV/AIDS. Since its inception in 1998 (a few years before the public sector response) AfA 
has made comprehensive HIV care available to over 80 000 people. The elements of the 
programme include encouraging voluntary counselling and testing (VCT) of its members; 
ART for adults and children; post exposure prophylaxis and PMTCT.  
 
Usage of ARV for PMTCT in the program has gone through various phases. In 1998 AZT 
250mg was given twice a day from 34 weeks gestational age (mono-therapy). In 1999-2001 
some women received AZT and 3TC from 34 weeks gestational age (dual therapy).  
In 2002 HAART-triple therapy was given from the 2nd trimester onward. This comprised 
of AZT and 3TC (Combivir®) and either NVP or lopinavir and ritonavir (Kaletra®). 
 11 
Pregnant women attend private obstetricians where HIV testing is almost routinely 
performed. HIV positive women are enrolled in the PMTCT program. AfA facilitates the 
clinical and financial management of each patient by the responsible medical practitioner, 
within the framework of a comprehensive and confidential disease management 
programme.  
  
In summary HAART is given to the women, elective Caesarean section is performed, AZT 
is given to the neonate and formula feeding is supplied for six months. HAART is provided 
regardless of the CD4 count, but patients with high CD4 counts are counselled about 
stopping therapy after delivery (in order to limit toxicity and preserve future options).  The 
CD4 count is monitored post delivery until the CD4 count is < 350 then HAART is 
indicated. 
 
Combivir® and Kaletra® are recommended to HIV positive pregnant women with a CD4 
count >250. Combivir® and NVP are used if CD4 count < 250.
37
 It has been recommended 
that NVP should not be prescribed in women with CD4 count >250 due to the increased 
risk of toxicity such as hepatitis and rash. The use of dual nucleoside therapy alone (e.g. 
Combivir®) for PMTCT is discouraged because of the risk of developing 3TC resistance.
37 
In all cases infants receive AZT suspension for 6 weeks (4mg/kg/dose twice a day starting 
8–12 hours after birth). Full blood counts are recommended at 2 to 3 weeks to exclude 
anaemia or neutropaenia. Formula feeds are authorized for six months (2kg/month).  
 
A qualitative HIV Polymerase Chain Reaction test (PCR) should be performed on the 
infants at 4-6 weeks to determine if infection has occurred. PCR is the preferred virological 
method for diagnosing HIV at less than 18 months of age. This is a qualitative HIV DNA 
PCR that is 40% sensitive within 48 hours, 90% sensitive within days and 99.9% sensitive 
by 6 months. Detection of HIV antibodies via the relatively inexpensive Enzyme Linked 
Immunosorbent Assay (ELISA) after 18 months confirms infection. 
 12 
A study conducted by AfA concluded that HAART for 1 month is more effective than 
HAART for <1 month, or mono- or dual-therapy for PMTCT.
38
 The data supported the use 
of HAART for a minimum of 2 months for effective PMTCT. It also revealed that 
transmission in “low risk” settings (plasma viral load <log 10
4
 or CD4 >500) is still 
significant and HAART should be considered for all pregnant women. The Caesarean 
section rate was >84%. The respective HIV transmission rates were similar for mono 
(5.2%), and dual therapy (6.3%), but tended to be lower for HAART (1.5%). AfA is in the 
process of reviewing their results, but preliminary data suggests a transmission rate of <1% 
in those women who are fully compliant. (Regensberg, L. Specialist physician. Personal 
communication. 9
th
 February 2009.) 
 
Practitioners in the private sector may opt to use different treatment regimens depending on 
the cost factor. There are many independent practitioners. There are no enforced rules and 
regulations. There are no peer review programmes and neither is there any audit of clinical 
practice. Not much data is available of the outcome of infants born to HIV positive mothers 
managed in private practice. In view of this, the present study aimed to assess success or 
otherwise of PMTCT in private paediatric practice in South Africa. 
 
Aim: To assess the PMTCT outcome in a group of infants attending paediatric practices in 
Central Durban. 
 
Research Hypothesis: The outcome of infants receiving PMTCT in the private sector is 
comparable with that in the developed world. 
 
Objectives: To describe in this group:   
-  HIV transmission from HIV positive mother to child  
-  Any relationships between outcome and maternal or paediatric characteristics such as:  
 Viral loads  
 CD4 counts  
 Antiretroviral regime  





















Ethical approval was obtained from the Biomedical Research Ethics Committee of the 
Nelson R Mandela School of Medicine South Africa (Reference number BEO47/47) 
(Appendix 1). No individual patient consent was deemed necessary as this was an 
anonymous chart review. Personal information remained confidential and personal 
practices were not identified 
 
2.2 Study Design  
 
This was a retrospective descriptive study. 
 
2.3 Setting  
 
In order to achieve the objectives of the study a suitable private sector population was 
chosen. The setting for the study was private paediatric practices in the Central region of 
Ethekweni Metro area of KwaZulu Natal.  
 
All the service providers were in the clusters of the planning area as follows. Durdoc 
Centre; Durban Medical Centre; Maxwell Centre (Durban CBD and Warwick area); 
Parklands Hospital and Nu-Shifa Hospital (Umgeni South including Springfield, 
Sydenham, Sparks Estate, Clare Estate); St Augustine’s Hospital and Entabeni Hospital 
(Berea North including Musgrave, Morningside, Essenwood) (Singh, V. Department of 
Planning, Ethekwini Municipality. Personal communication. 20
th
 November 2008). 
 
There are approximately 20 paediatric practitioners in this geographic area. Letters were 
sent to all paediatricians practicing in this region asking them to participate (Appendix 2). 
Many of the patients who attend the private health sector belong to private medical 
schemes and there are a few that can afford out of pocket payment for medical care. Many 
belong to a large group administration called AfA.  
 15 
2.4 PMTCT Program in Private Sector 
 
This was as per the AfA recommendation for PMTCT as outlined in 1.3.2. 
 
2.5 Study Population 
 
The Study Population was all infants (HIV exposed) born to HIV positive mothers who 
attended the paediatricians who agreed to participate.  
  
2.6 Selection of Study Population 
 
There was no sampling method as the charts of all the infants born to HIV positive mothers 
for the study period in the practices of the paediatricians who agreed to participate were 
reviewed. The inclusion criteria were all HIV exposed infants. Records of infants born 
between January 2004 and June 2005 were reviewed.  
 
2.7 Data Collection  
 
Data was collected by means of a questionnaire that was sent to those paediatricians who 
agreed to participate. This questionnaire was structured in two parts: 
 
The maternal data, (Appendix 3a) consisted of questions regarding demographics, the 
diagnosis and treatment of HIV, mode of delivery, viral load and CD4 count. This data was 
accessed by the paediatrician from the maternal records obtained from the obstetrician. 
The baby data, (Appendix 3b) consisted of questions regarding the condition of the baby. 
The outcome of baby was their HIV status. This had been determined either by PCR or 
ELISA. 
 16 
The study was piloted with three paediatricians who, between them, completed five 
questionnaires. From the responses received the questionnaire was deemed feasible. In 
discussion with a statistician it was estimated that a sample size of 98 would be appropriate 
and would satisfactorily represent a subset of a larger population at any given time.   
 
2.8 Data Analysis 
 
All responses per question on the questionnaire were given a numeric value that was used 
for coding (Appendix 4). The coded data was then entered as a dataset into a Microsoft 
Excel Spreadsheet. The data entry was checked and errors were corrected.  
 
2.9 Statistical Analysis  
 
Consultation with a statistician revealed that a sample size of 98 was acceptable to get a 
95% confidence interval of 0-4.7% around an estimated true population prevalence of 
transmission of 2% with an estimated population size of 2000 HIV-infected women in the 
18 month period.
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The final sample size was increased to 101 infants. Data were captured 
and analysed using SPSS 15 (SPSS Inc., Chicago, Ill). EpiCalc 1.32 was used to calculate 
95% confidence intervals. Data were presented in frequency tables, histograms, bar 




















3.1 Participating paediatric practices 
 
Of the total of 20 paediatricians in the Durban Central Area, four (20 %) did not respond to 
the request. Eight (40%) agreed to participate. The main reason given by those who did not 
wish to participate (40%) was the fact that they did not do relevant neonatal work and 
would therefore not be able to contribute patients. Three were sub-specialists paediatric 
cardiologist (1) neurology (1) haematology (1) respectively, two were in limited private 
practice and three were scaling down their practices. 
 
One hundred and one charts were made available by the paediatricians in these eight 
practices. The paediatrician, when necessary accessed maternal records from the 
obstetrician to extract the relevant maternal data. Fifty of these came from a single practice 
due to fact that this particular practitioner was a referral centre for pregnant HIV positive 
women and paediatric HIV patients. The balance of the charts was contributed 
approximately equally by the remaining practitioners, providing an average of seven 
patients per practitioner.  
 
3.2 Details of women 
 
3.2.1 Demographic and clinical details 
 
The 101 infants were delivered of 100 Black African HIV positive women (one woman had 
a set of twins). Infants were delivered as follows in the respective hospitals: 26 at City 
Hospital, 67 at St Augustine’s Hospital and 8 at Parklands Hospital. Ninety-seven patients 
were on medical aid of which 86 were contracted to AfA. The mean age of the women was 
29.85 years (SD 5.38; range 18-44 years) and more details are shown in Fig.1. The mean 
parity of the women was 1 child (range 1-4 children) and more details are given in Fig.2. 
The trimester at first presentation and at which antenatal care was initiated is shown in 
Fig.3. The mean gestational age at presentation and antenatal care initiation was the first 
trimester. Diagnosis of HIV infection was made in the current pregnancy in 75 cases. Prior 


















































































Fig.3 Trimester in which antenatal care initiated in HIV positive mothers (n=100) 
 
3.2.2 Viral load and CD4 counts 
 
Eighty six and 91 of the women had recorded viral load and CD4 count measurements, in 
their antenatal records, respectively. The median CD4 count was 426 (IQR 244-613). Only 
13% of the women had CD4 counts less than 200. The median viral load at first 
presentation was 3.97 logs (IQR 1.6-5.8) or 11 391 copies/ml (IQR 2 013-41 502).  
 
3.2.3 Prophylactic regimen  
 
Only five women had no prophylactic treatment at all. Of the remaining 95, 86 women 
(90.5%) had HAART and in all cases this regimen included intrapartum intravenous AZT. 
Nine women did not receive HAART but had other prophylaxis: seven received only 
intrapartum intravenous AZT, one had only NVP at delivery and one had dual therapy with 
Combivir®. In 73 women treatment had been initiated at less than 34 weeks of gestation, 
72 of these were women who received HAART and one was the patient who had 






























Fig.4 ARV treatment initiation in pregnant mothers (n=100) 
 
3.2.4 Mode of Delivery 
 
Ninety three and seven mothers had deliveries by caesarean section and normal vaginal 
delivery respectively (Fig.5). The reasons for the normal vaginal delivery were as follows: 
one was too sick for caesarean section, one opted for a vaginal delivery, and five presented 
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Fig.5 Summary of Maternal Results 
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3.2.5 Maternal disease during pregnancy and post-delivery complications  
 
Although 14 patients had some associated problems as detailed below, none of these 
mothers delivered HIV-infected infants. 
 One had severe anemia (Haemoglobin (Hb) 6g/dl) and was transfused prior to 
delivery. 
 Two had postnatal depression (one of whom already had pre-existing bilateral 
amputation of lower limb due to prior car accident). 
 Three had tuberculosis diagnosed during pregnancy (two pulmonary, and one 
abdominal).  
 One had severe pregnancy induced hypertension (PIH) and delivered a preterm 
baby. 
 Two had wound sepsis (one poor wound healing associated with syphilis; the other 
needed secondary suturing of dehiscence of the wound). 
 Four incidental findings of grade 3 cervical intraepithelial neoplasia at six weeks 
post natal check up.  
 One maternal death at 6 weeks due to pneumonia and diarrhoea. Although she had 
been on HAART since 2002 her viral load was 80 594 and CD4 count was 423. Her 




3.3 Details of infants 
 
3.3.1 Demographic details 
 
The study group comprised 101 Black African infants, half of whom were boys. Seventy 
nine were average birth weight (2.5-4kg), 20 were low birth weight (< 2.5kg) and two were 
large for gestational age (> 4kg). Eighty three were born at term and 18 were born preterm.  
 
3.3.2 Clinical and medication details 
 
All infants had been formula fed and had received AZT syrup for 6 weeks as per the AfA 
protocol. Hb had been measured at six weeks in 98 of the patients and 18 had anaemia (Hb 
<10 g/dl) of whom only 4 were preterm. Cotrimoxazole for PCP prophylaxis was recorded 
in 79. Thirteen had no records and nine were not given any prophylaxis. 
 
Fifteen infants were unwell at birth. Three of these were term infants: one had transient 
tachpnoea of the newborn, which resolved, and the other two were intrauterine grow 
retarded infants (IUGR) .One of these IUGR infants died before HIV testing and the other 
did not return for PCR or ELISA testing. No cause for the IUGR was found in the charts 
 
Twelve were preterm (average birth weight 1.5kg and average gestational age 34 weeks) 
and presented with common problems frequently encountered in prematurity such as 





3.4 Outcome of infants 
 
Of the 101 baby charts, information about HIV diagnosis was unknown in nine. Eight did 
not return for testing. One died at 5 weeks, before testing. This was the unexplained 
intrauterine growth retardation (IUGR 1.9kg) term baby. The cause of the neonatal death 
remains unknown but on verbal autopsy the mother reported that the baby had been well 
post discharge and had died from a bleeding cord 5 weeks post delivery. No autopsy was 
performed. This infant was born to a 29 year old P1G2 who initiated HAART therapy 
under 28 weeks and whose viral load and CD4 count were 1109 copies/ml and 242 
respectively. A summary of the paediatric outcomes is given in Fig.6. 
 
Ninety two infants were tested, 61 at the first PCR, five of whom had a second PCR. Fifty 
six were tested by ELISA at 18 months (some of whom had already had a first PCR) 
(Fig.7). Two infants were diagnosed positive. The transmission rate excluding the 9 
missing infants was 2.17% (95% CI: 0.38-8.38). The transmission rate including the 9 
missing infants was 1.98 (95% CI: 0.34-7.66) (Table 1).  
 
The two positive infants were both diagnosed at six weeks on the initial PCR test (Fig.8). 
HAART was subsequently initiated in both cases. The first positive infant was born to a 28 
year old Primip who was diagnosed two years prior to pregnancy but presented very late 
for antenatal care. She did not have any antenatal component of PMTCT but had a preterm 
caesarean delivery at 33 weeks, intrapartum AZT intravenously and the preterm AGA 
2.2kg (who had congenital pneumonia and anaemia) baby was given 6 weeks of AZT. No 
viral load and CD4 were available at the time of delivery. The other positive infant was 
born to a 37 year Para 2 Gravida 2 who confirmed pregnancy and was tested early but did 
not return timeously for management. She had only one week of HAART prior to a term 
caesarean delivery, intrapartum AZT intravenously and the term AGA baby was given 6 
weeks of AZT. The maternal viral load was 50 000 and CD4 was 327. A summary of the 










 Fig 6 Summary of paediatric results       26 
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 Frequency Percent Valid Percent 
Positive 2 1.98 2.17 
Negative 90 89.11 97.83 
Total 92  100 
Missing 9 8.91  





















































The results of the present study indicate that the PMTCT programme in the private sector 
in central Durban from January 2004 and June 2005 achieved a positive outcome in that 
there was a low rate of vertical transmission of HIV. The transmission rate of 2.17 % 
would increase to 3.2% if the single neonatal death is included. This compares very 
favourably with the result 8.8% for the Western Cape (dual therapy)
32, 33
 and does 
exceptionally well compared to the 20.8% for the KwaZulu Natal public sector 
(monotherapy).
29
 Other countries in Africa still fare very badly, transmission is still as high 




Prevention of MTCT programs have succeeded in other developing countries e.g. Thailand, 
Brazil and Cameroon
4, 8
 and now, more recently, in Botswana.
40
 A country with strong 
political commitment, Botswana has shown the way forward for other countries in Africa. 
It has lowered MTCT to less than 4%. Botswana was one of the first countries in Africa to 
establish a national antiretroviral therapy programme in 2002. This programme includes 
routine HIV testing; AZT at 28 weeks and sdNVP in labour and the infant is given four 
weeks of AZT and sdNVP. Only recently did South Africa amend the PMTCT schedule to 





The cause of the neonatal death (unexplained IUGR infant ) remains unknown, but on 
verbal autopsy the mother reported that the baby had been well post discharge and died 
from a bleeding cord 5 weeks post delivery. Although the findings from the South African, 
Children with HIV Early Antiretroviral Therapy (CHER) Study Team demonstrated that 
HIV infection contributed significantly to infant mortality,
 41
 it would seem unlikely that 
this infant was HIV infected given the fact that the mother had a low viral load and had 
initiated HAART at less than 28 weeks of gestation. 
If this neonatal death is excluded then the rate (2.17 %) compares favourably with the 2.9% 
from the McCord experience. Thus far the most promising reduction in vertical 
transmission rate in South Africa has come from the McCord PMTCT programme, a 
smaller, non-governmental project in Kwa Zulu Natal.
34
 However, as discussed later, the 
 31 
McCord study group had double the number of women with low CD4 counts and half the 
number receiving HAART. When this is considered, our outcome is actually less 
favourable than theirs. 
  
The result of 2.17 % transmission in this study is in line with Europe and the USA, where 
fewer than 2% of babies born to HIV positive mothers are infected.
12
 However, this figure 
is still slightly higher than the transmission rate of less than 1% expected according to the 
AfA preliminary data in women who are fully compliant (Regensberg, L. Specialist 
physician. Personal communication. 9
th
 February 2009). The two infected infants in the 
present study were as a result of poor maternal compliance. If these two are excluded then 
the transmission rate is actually less than 1%. This then, will be consistent with the 
expected transmission rate of less than 1% according to the AfA.
 
The numbers are small in 
the present study but they lead one to the hope that with appropriate compliance one could 




The number that did not return for testing (9%) is a problem consistent with other studies. 
Although high, this is slightly less than the 11% in the McCord’s study.
34
 Another PMTCT 
study, involving a number of different resource limited countries, also reported a 
significant loss to follow-up (although the exact percentage was not stated).
42 
If the loss to 
follow up are all considered positive then the transmission rate would rise to an 
unacceptable high 10%. However, in studies of this nature the loss to follow up are 
considered negative (Esterhuizen, T. Statistician. Personal communication. 9
th
 March 
2009). In addition, there is only a 30-45% possibility of overall vertical transmission in the 
absence of any preventative strategy.
4 
 
The loss to follow up in the present study could be attributed to the following factors: 
another paediatrician may attend to the newborn post discharge; the infant may not be 
registered on the medical aid scheme and there is reluctance to pay out of pocket for 
services; fear of the outcome and, in some instances, there is non-disclosure of the HIV-
 32 
infected status to partners; and poor counselling during and post delivery, regarding infant 
testing. 
 
Follow up could be greatly improved, in the private sector, if all infants were automatically 
registered on the medical aid as soon as they were born. Counselling of mothers, regarding 
the necessity of early testing of their infants, also needs to be improved. 
 
Maternal viral loads and CD4 counts are often used as markers for the prediction of risk of 
MTCT. The CD4 count is often used as a guide to the health status of the women. The 
majority of patients had viral load and CD4 count results, because most medical aids paid 
for these tests. Although the numbers were small, the median CD4 count 426 (IQR 244-
613), was higher than the median CD4 count 293 (IQR 195-451) of the McCord study.
34 
Also fewer of the patients (13%) in this study compared to McCord (26%) had CD4 < 200. 
This suggests that the women in our study had better preservation of immune function 
although the median viral load was slightly higher. The median viral load here was 3.97 
logs (IQR 1.6-5.8) or 11 391 copies/ml (IQR 2 013-41 502) compared to the median viral 
load at McCord 3.9 logs (IQR 3.1-4.6) or 7 787 copies/ml (IQR 1 403-39 856).  
 
It thus appears, that the present study patients were more advantaged than the McCord 
group and yet did not fare as well. In this study neither the viral load nor CD4 count result 
was related to the outcome of the infant and HAART was used in pregnancy irrespective of 
their values. A larger number of patients (87%) in the present study received HAART 
compared to 44% of the McCord group. This high percentage of HIV positive pregnant 
women receiving HAART is in line with the USA, where the proportion of women 




Almost all the women were on private medical aid schemes, many of which are affiliated to 
the AfA programme. Their recommendations are derived from those of the developed 
countries. The following factors greatly influenced the positive outcome: early antenatal 
care, almost routine HIV testing, early initiation of HAART, elective caesarean delivery, 
avoidance of breastfeeding and a long course of ARV given to the infants.  
 33 
These are similar reasons which have led to the falling perinatal transmission rates in the 
developed world.
11
 Often the medical aid administration reminds patients of investigations 
and encourages drug adherence. This approach helps to ensure adherence and good follow-
up. 
 
The fact that almost all of the patients were on private medical aid (having access to 
HAART) is indicative of a higher socioeconomic population than the rural areas where the 
majority of the pregnant women are unemployed and poor.
44 
The average age of the 
pregnant women was 30 years and most were primigravid. This is in line with the situation 
seen in the developed world where an increasing proportion of births occur in women of 
advanced maternal age unlike developing countries where teenage pregnancy is still a 
problem.
44, 45  
 
Antenatal care is aimed at improving the general health status of pregnant women and also 
serves as an entry point for early VCT and is crucial for the provision of PMTCT 
strategies. Almost half of the women confirmed pregnancy and initiated antenatal care in 
the first trimester as opposed to public sector where local surveys of antenatal patients in 
Gauteng and in KwaZulu-Natal further demonstrated that the majority of women 




Most of the women were diagnosed with HIV in the current pregnancy (76%). This 
supports the contention that PMTCT is an effective tool for determining one’s status. 
However, it must be noted that HIV testing is almost routine in the private health care 
sector, although patients do have the option to decline unlike the public health care sector 
where there is VCT.  
 
Counselling in the private sector is done by the health practitioner. Patients are not usually 
referred to a psychologist or an HIV counsellor in the private setting unless there is a 
specific indication to do so. This may be seen as a deficiency in the private sector.
46, 47
 The 
Centres for Disease Control and Prevention (CDC), in April 2003, recommended a strategy 
where all women are tested in the antenatal period for HIV as a means to increase testing 
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rates unless they decline i.e. “opt-out”. The intention is to streamline HIV testing so that 
the extensive requirement for pre-test counselling is reduced.  
 
Under the CDC interpretation of opt-out, pre-test counselling should be replaced by written 
information on HIV transmission and prevention. In addition, testing for HIV in pregnant  
women should be a part of the routine battery of prenatal blood tests. Refusal is to be 
documented in the woman's medical record, in lieu of signed informed consent. This is a 
recommendation that should be considered in South Africa. On the other hand, this may not 
be in keeping with the trend and guidelines to have trained counsellors, with the skills to 
manage the situation. Such trained counsellors would ensure confidentiality and build 




In this study the Caesarean section rate (94%) was higher than in the McCord Hospital 
(70%) PMTCT programme. There were hardly any operative or post operative 
complications. The safety of the private health sector is demonstrated. This is in line with 
trends elsewhere; such as in USA and in Europe.
11, 48 
It was also noted that only two of the 
women who had a caesarean section had wound sepsis.  
 
A study in the public sector, found women who were HIV positive were at risk from dying 
following a normal vaginal delivery (even in the absence of AIDS defining features) and 
this risk was increased following caesarean section.
49
 Although one maternal death 
occurred in the study group, this was at 6 weeks and was thus unrelated to postoperative 
complications; her baby was HIV negative. 
 
Fourteen patients had viral loads less than 1000 copies/ml and still had deliveries via 
caesarean section. Earlier studies have shown that no transmission occurred where the 
maternal plasma viral load was less than 1 000 copies/ml and less than 500 copies/ml 
irrespective of the mode of delivery.
11 
Currently in the USA, caesarean section is only 
recommended for women with a viral load of greater than 1000 copies/ml. However 
current plasma viral loads have lower limit of detection (as low as 50 copies/ml).  The UK 




However, a more recent meta-analysis of seven prospective studies demonstrated 44 cases 
of perinatal HIV transmission among 1202 women with plasma viral loads of less than 
1000 copies/ml at or near the time of delivery.
50
 At present the data suggest, there is 
insufficient evidence to define a plasma viral load threshold below which transmission 
never occurs.  
 
HIV infection has been reported to have little effect on pregnancy outcome in the 
developed world, however early studies from sub-Saharan Africa suggest that infants of 
HIV-infected women may be at increased risk of adverse pregnancy outcomes such as 
lower birth weight, prematurity and perinatal and neonatal death.
51 A study of HIV-infected 
pregnant women in rural and urban South Africa found that maternal HIV infection was 
associated with an approximately 45% increased risk of having low birth weight infants. 




The present study found that the majority of the infants (79%) were of average birth weight 
and that 18% were preterm. Considering that the women in the present study came from a 
well resourced population, this percentage of prematurity is considerably higher, and 
inconsistent with that expected for developed countries (7%). It is rather more consistent 
with the 16.5% reported for developing countries.
53 
The South Africa prematurity rate may 




It has been suggested that the use of combination ART regimens before or early in 
pregnancy may slightly increase the risk of prematurity and that there is a significantly 
increased risk of premature delivery with protease inhibitor containing versus non- protease 
inhibitor containing combination therapy.
55
 In the present study a large percentage did start 
ARV including protease inhibitor early in the pregnancy. However, a recent meta-analysis 
of published data concluded that, overall, the use of ART in pregnant HIV-infected women 




There is an increased risk of HIV transmission with prematurity.
7
 In the present study only 
one of the 18 premature infants was HIV infected and in that particular instance the woman 
had suboptimal prophylaxis. However the numbers here are far too small to say whether 
prematurity is or is not associated with an increased risk for HIV transmission.  
 
Although the WHO/UNICEF/UNAIDS guidelines recommend exclusive breastfeeding for 
HIV-infected women for the first six months of life, all the infants in this study were 
formula fed as this was already approved by the medical aid as part of the protocol. This is 
in line with the further recommendation that where replacement feeding is acceptable, 
feasible, affordable, sustainable and safe, avoidance of all breastfeeding by HIV-infected 
women is recommended.
57
All these factors were present to make replacement feeding 
acceptable in this study.  
 
Avoidance of breastfeeding for some women is difficult and may be considered a sign to 
others of the mother’s HIV status. The possibility, that some women receiving HAART, 
could breastfeed safely has been raised. The DREAM study in Mozambique demonstrated 
that breastfeeding among HIV-infected mothers receiving HAART posed no additional risk 
of late postnatal HIV transmission to the infant by 6 months of age.
58
 Another study 
provided good data that replacement feeding can be a safe option to consider for HIV-





Eighteen infants had anaemia of whom four were preterm. This was expected as all the 
infants were given AZT. Studies have shown that the only short-term
 
toxic effect directly 
attributable to AZT is anaemia,
 
which is mild and reversible.
10
 
The current CDC guidelines for reasonable exclusion of HIV in an infant require two 
negative PCR tests, one of which should be performed at 1 month of age or older, and the 
other at 4 months of age or older. A positive PCR at any time requires a repeat test on a 
second blood sample as soon as possible for confirmation.
60 
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Sixty percent had only the first PCR and some opted only for the cheaper ELISA test at 
eighteen months. This reluctance was due to concerns, of both practitioner and patient, that 
the costly PCR would deplete the medical aid funds earlier. In addition, this study was in 
the early stages of the PMTCT programme when mothers were reluctant to have their 
infants tested and practitioners did not appreciate the need for early testing and thus did not 
influence their patients accordingly. Subsequently there was a lag in diagnosis.  
The WHO recommends that PCP prophylaxis in HIV exposed children continue to the age 
of 15 months, but suggests it be stopped earlier if HIV infection has been ruled out by 
PCR.
61
 Studies by McNally et al.
62 
and Jeena et al.
63
 have suggested that besides HIV-
infected children, the HIV exposed, but uninfected child, also seem to be at risk of 
acquiring PCP. Thus, they suggested that the WHO guidelines be reviewed and that PCP 
prophylaxis be continued in all HIV exposed infants. However, despite this 
recommendation, of the 32 cases of proven PCP in the McNally study only three were HIV 
exposed uninfected, while five of 52 identified PCP were HIV exposed uninfected in the 
Jeena study. 
A previous study in KZN suggested that the HIV status of infants be determined as early as 
six weeks in order to prevent unnecessary exposure of uninfected infants to PCP 
prophylaxis because of a possible association between cotrimoxazole and an increased risk 
of diarrhoea.
64
 There is the additional public health risk that unnecessary treatment in this 
much larger group of HIV exposed children will increase resistance to the drug. In the 
present study cotrimoxazole was given to a large number (78%) of infants to prevent PCP. 
Therefore many infants were given cotrimoxazole who did not actually need the 
prophylaxis. Another study in Abidjan demonstrated that the cost benefit of early testing 




Of the two patients who tested HIV positive, the mother of the first was diagnosed two 
years prior to the pregnancy but presented very late for antenatal care. The mother of the 
second baby tested early but did not return for results. In both cases effective treatment 
could not be instituted timeously.  
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Had both these mothers taken their condition more seriously and sought appropriate 
treatment and been better counselled, the outcome for their babies may well have been 
different. There is thus evidence of denial and lack of insight into the condition. Non 
adherence is a risk factor in perinatal transmission but this is a problem that even a 




BIAS AND LIMITATIONS  
 
This study may have been subject to selection bias. A large number of the completed 
questionnaires came from one particular practitioner because this was a referral centre. In 
fact, all the health care providers who participated were probably more aware and 
knowledgeable of the PMTCT protocol than average practitioners due to special interest in 
the field. Thus the results may not be extrapolated to the whole of the private sector.  
 
Furthermore, almost all (97%) of these patients were on a private medical aid and therefore 
may be socio-economically and educationally better off. This may influence health and 
compliance and may therefore not be extrapolated to the general antenatal population who 
may attend the private sector.  
 
This study relied on data collected from records of all infants of HIV positive mothers who 
presented at the paediatrician’s practice for follow up. Infants of pregnant women who did 
not know their HIV status, and also some pregnant women who were offered VCT and may 
have opted out, were excluded.  
 
There may have been errors in written records. Such a possibility always exists when 
collecting retrospective data. 
 
Another limitation of this study is that the sample size was small and therefore it may not 















Children are the innocent victims of this deadly epidemic. By decreasing vertical 
transmission, the incidence and suffering of many children will be ameliorated. The results 
of the present study indicate that the PMTC program of the private sector in central Durban 
from January 2004 and June 2005 achieved a positive outcome with regards the reduction 
of vertical transmission of HIV. It must be noted that the two women whose infants were 
HIV infected did not have optimal PMTCT as recommended.  
 
Thus the transmission rate was actually less than 1% in those women who were fully 
compliant. This is in line with the transmission rate of less than 1% expected according to 
the AfA preliminary data in fully compliant women. It is also similar to the developed 
world, were the transmission is down to about 1% or 2%. Although the study sample was 
small, the results indicate the possibility of the virtual elimination of MTCT of HIV in the 
private sector provided the recommendations are followed. Early antenatal initiation and 
adherence to HAART could have averted these two cases that were infected. 
 
The PMTCT protocol recommended by the medical aids are guidelines based on the 
recommendations of the developed world. The excellent results are also indicative of 
resources available. The private healthcare sector may be seen by some as elitist and only 
caring for the “haves”, at the expense of the “have nots”. However, lessons can be learnt 
from each sector, as expounded in the Health Charter which promotes a partnership 
between both the public and the private sector. The present research finding is indirectly a 
means of sharing such information and building partnerships. 
 
The success of decreasing perinatal HIV would be a huge boost to overall infant and child 
mortality and morbidity. However, there is no room for complacency as the number of HIV 
positive women having babies continues to increase. Worldwide and country level efforts 
are needed to scale-up HIV prevention, care and treatment for all strata of society: men, 
women and children, rich and poor alike. This can be achieved by effective leadership, 




Recommendation as a result of the study findings are as follows: 
 All pregnant women should have HIV testing and realise the necessity of early 
prophylaxis and adherence to protocols in PMTCT. 
 
Further recommendations for the success of PMTCT based on personal experience and 
from the literature are as follows: 
 PCP prophylaxis could be stopped as soon as possible in HIV exposed but 
uninfected infants. 
 Testing for HIV in pregnancy should be a part of the routine battery of antenatal 
blood tests. 
 The extensive requirement for pretest counselling should be reduced. 
 Doctors should be trained with basic counselling skills. 
 Efforts to increase PMTCT should be scaled up. 
 Pretest counselling could be replaced by written information on HIV. 
 Refusal of an HIV test is to be documented in the woman's medical record, in lieu 
of signed informed consent. 
 All women who receive antiretroviral therapy in pregnancy should be registered 
prospectively into a register like the Antiretroviral Pregnancy Registry in the UK. 
 Women should be advised to continue follow up and monitoring. 
 Other cheaper tests should be developed to allow early diagnosis. 
 The private sector should replace the whole blood PCR testing with heel prick dried 
blood spot test as done in the public sector. Although not cheaper, the advantages of 
this test include the following: that it does not need the expertise required for 
venesection, there is reduced biohazard status once dry, and there is no need for 

















1 INFORMATION DOCUMENT  
 
Study title: A Descriptive study of Prevention of mother-to-child transmission 
(PMTCT) of HIV in Private Practice in Central Durban 
 
 1.1. Dear Dr ……………………………. 
 
Introduction: 
I, Dr Shakira Cassim (Paediatrician), am doing a research study as part of my 
requirement towards a Masters in Public Health with the University of KwaZulu Natal. 
(School of Family and Public Health Medicine, Nelson Mandela School of Medicine). 
In this study we want document the outcome of infants born to HIV positive mothers 
managed in private practice in Central Durban. 
 
The objectives are to describe: 
 Trends of transmission rate from HIV positive women to baby 
 Trends between maternal CD4, viral loads and outcome 
 Trends of antiretroviral regime  
 Trends in mode of delivery 
 Trends in feeding practices 
 
1.1.2 Not much is known about what happens in private practice with the regards the 
above topic. 
 






What is involved in the study?  
 
There are approximately 20 paediatric practitioners in this geographic area. The area is as 
follows: Durdoc Centre (Smith Street); Durban Medical Centre and Maxwell Centre 
(Beatrice and Lorne Street area); Parklands Hospital and Nu-Shifa Hospital (Overport); and 
St Augustine Hospital and Entabeni Hospital (Glenwood).  
 
This will be a retrospective descriptive study of patient records from participating 
paediatricians between January 2004 to June 2005. The birth period has been chosen such 
as to ensure that all infants during the data collection period (May – October 2007) will 
between 15 - 18 months old.  
 
The inclusion criteria will be all HIV exposed infants.  The outcome of infants will be their 
HIV status. This will have been determined by PCR or Elisa test.  Certain other 
demographic and clinical data regarding the infant will be sought from the paediatric 
records.  
 
The paediatrician will also be asked to collect certain corresponding maternal demographic 
and clinical data. The study may entail a data collector collecting data (Should you be to 
busy). 
 
Data collection: May to July 2007 
Collation and analysis: August to October 2007 
Submission: November 2007 
 
There are no risks of being involved in the study, 
 
The benefits of being in the study include the collection and analysis of information  
which might be advantageous to you and others. 
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You will be given pertinent information on the study while being involved in the project and  
after the results are available. 
 
Participation is voluntary, that refusal to participate will involve no penalty or loss of benefits  
 
Confidentiality: Efforts will be made to keep personal information confidential.  Personal  
practices will not be identified. 
 
Contact details of researcher/s – for further information please contact: 
 
 Shakira Cassim  (Cell 083 786 3047), 7TH Floor, Durdoc Centre,  
 460 Smith Street, Durban 
 Supervisor: Prof Julia Botha, Department of Therapeutics and Medicine Management, University of 
Kwa Zulu Natal, Telephone (031)260 4333 
 
Contact details of administrator – for reporting of complaints / problems: 
 Department of Therapeutics and Medicines Management  
 School of Family and Public Health Medicine,  
 Nelson Mandela School of Medicine,  
University of Kwa Zulu Natal, Telephone 031 –260 4334 
 
BREC administrator:  
 Mrs. Buccas 
Nelson R Mandela School of Medicine, Private Bag 7, Congella 4013 
Telephone : 27 31 260 4796 
Fax  : 27 31 260 4609 




(a) MATERNAL DATA 
1.  Health care     : Medical aid  Private 
2.   Date of birth    : _______________________________ 
3. Place of Delivery    : _______________________________ 
4. Gestational Age    
When pregnancy confirmed  : _______________________________ 
When antenatal care initiated  : _______________________________ 
5. Parity     : _______________________________ 
6. Date of HIV Diagnosis  : _______________________________
 (If actual date not known approximate) _______________________________ 
7. Drug History    :  ARV Medication and  Duration 
       _______________________________ 
      : Monotherapy 
: Dual                  
: HAART 
  Any other treatment    : _______________________________ 
 Initiation of Treatment     
  When     : _______________________________ 
8. Mode of Delivery   : NVD  C/S  Assisted 
9. Investigation      
Results    : Viral Load  CD4 
 Date     : _______________________________ 
11. Post Delivery Complication  : _______________________________ 
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(b) BABY DATA 
  
1. Date of birth          : _______________________________ 
2. Race     : _______________________________ 
3. Sex      : Male   Female 
4. Birth Weight    : _______________________________ 
5. Gestational    : Term   Preterm 
       AGA   SGA 
6. Condition @ birth   : Well  Sick (details) 
       
7.    Feeds     : Breast  Formula  
 Duration    : ______________________________ 
8. ARV prophylaxis    
Drug     : ______________________________ 
Duration    : ______________________________ 
Adherence    : ______________________________ 
9. FBC        
 Result     : ______________________________ 
Date     : ______________________________ 
10.  PCP Prophylaxis      
 Duration      : ______________________________                                                             
 Adherence     : ______________________________ 
11.  Outcome @ 18mnths    
 1
st
 PCR    : Positive  Negative 
 2
nd
 PCR    : Positive  Negative  
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Appendix 4  
PRELIMINARY ANALYSIS OF RAW DATA 
 (a) MATERNAL DATA 
1. Age     : 15yrs     15-25yrs  
       25-35yrs   >35yrs 
2. Parity     : 0-1 child  2-4 children  
       > 4 children 
3. Diagnosis confirmed   : Previously Current Pregnancy 
4. ARV regime    : Dual Therapy  HAART 
5. Initiation of Treatment  : < 28 weeks 28 – 34 weeks   
        >34 weeks 
6. Mode of Delivery   : NVD  C/S 
7. Viral Load    : < 1 000 1 000 – 5 000   
       > 5 000 
 CD4     : < 200  200 – 500 > 500 
8. Post Delivery  
 Complications    : Absent  Present 
(b) BABY DATA 
1. Birth Weight    : < 2.5kg 2.5kg – 4kg  > 4kg 
2. Condition @ birth   : Well   Sick 
3. Feeds     : Breast  Formula 
4. ARV - AZT @ 6 weeks  : Yes  No 
5. Anaemia    : Yes  No 
6. PCP Prophylaxis   : Yes   No 
7. Outcome @ 15 months  
 1
st
 PCR    : Positive  Negative 
 2
nd
 PCR    : Positive Negative 
 Elisa >   !8 months   : Positive  Negative 


















1. Report on the global HIV/AIDS epidemic 2008. Geneva: UNAIDS; 2008. [cited 2008 
Nov 19]. Available from: URL:  
http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_re
port.asp  
2. Sub-Saharan Africa AIDS epidemic update regional summary. Geneva: UNAIDS; 2008. 
[cited 2008 Oct 20]. Available from: URL: 
http://data.unaids.org/pub/Report/2008/JC1526_epibriefs_subsaharanafrica_en.pdf 
3. Report [of] The National HIV and Syphilis Antenatal Sero-Prevalence Survey in South 
Africa 2006. Pretoria: Department of Health; 2007. [cited 2008 Aug 31]. Available from: 
URL: http://www.doh.gov.za/docs/reports/2007/hiv/part1.pdf 
4. Coovadia HM, Archary D. Prevention of Transmission of HIV-1 from Mothers to 
Infants in Africa. In: Pollard AJ, Finn A, editors. Hot Topics in Infection and Immunity in 
Children III. New York: Springer Science Business Media; 2006. p. 201-6. 
5. United Nations General Assembly Special Session on HIV/AIDS.  Monitoring the 
Declaration of Commitment on HIV/AIDS : guidelines on construction of core indicators. 
Geneva :UNAIDS; 2005. [cited 2008 Oct 18]. Available from: URL:  
http://data.unaids.org/Publications/IRC-pub06/JC1126-ConstrCoreIndic-UNGASS_en.pdf  
6. United Nations. Millennium Development Goals. End Poverty 2015.  [cited 2008 Nov 
29]. Available from: URL: http://www.un.org/millenniumgoals/bkgd.shtml  
7. Gray G, McIntyre J, Jivkov B, Violari A. Preventing Mother-to-child Transmission of 
HIV in South Africa. Southern African Journal of HIV Medicine 2001;2(2):15-26. 
8. Coovadia HM. Perspectives on paediatric HIV/AIDS: Prevention of mother to child 
transmission of HIV. Current Science 2008;95(9):1133-1149. 
9. Fiscus SA, Schoenbach V, Wilfert C. Short Courses of Zidovudine and Perinatal 
Transmission of HIV. N Engl J Med 1999;340(13):1040-1. 
10. Connor EM, Sperling R, Gelber P, Kiselev G. Scott, O'Sullivan MJ, et al..  Reduction 
of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine 
treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 
1994;331(18):1173-1180. 
11. Elective caesarean section versus vaginal delivery in prevention of vertical HIV-1 
transmission: a randomized clinical trial. The European Mode of Delivery Collaboration. 
Lancet 1999; 353(9158):1035–9. 
12. Cooper ER, Charurat M, Mofenson L,  Hanson IC, Pitt J, Diaz C, et al. Combination 
antiretroviral strategies for the treatment of pregnant HIV-1-infected women prevention of 
perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-494. 
13. European Collaborative Study. Mother-to-child transmission of HIV infection  in the era 
of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(3):458-65. 
14. Naver L, Lingren S, Belfrage E, Gyllenstenk K, Lidman K, Gisslen M. Children born to 
HIV-1-infected women in Sweden in 1982-2003: trends in epidemiology and vertical 
transmission. J Acquir Immune Defic Syndr 2006;42(4):484-9. 
15. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. 
Short-course zidovudine for perinatal HIV-1 transmission in Bangkok,Thailand: a 
randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study 
Group. Lancet 1999;353(9155):773-80. 
 53 
16. Lallemant M, Jourdain G, Le Coeur S, Kim S, Koetsawang S, Comeau AM, et al. A 
trial of shortened zidovudine regimens to prevent mother-to-child transmission of human 
immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N 
Engl J Med 2000;343(14):982-91. 
17. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, 
et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child 
transmission of HIV-1 in Thailand. N Engl J Med 2004; 351(3):217-28. 
18. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, 
et al. Lamivudine-zidovudine combination for prevention of  maternal-infant transmission 
of HIV-1. JAMA 2001;285(16):2083-93. 
19. Chalermchokcharoenkit A, Asavapiriyanont S, Teeraratkul A, Vanprapa N, 
Chotpitayasunondh T, Chaowanachan T, et al. Combination Short-course Zidovudine plus 
2-Dose Nevirapine for Prevention of Mother-to- Child Transmission: Safety, Tolerance, 
Transmission, and Resistance Results. 11th Conference on Retroviruses and Opportunistic 
Infections, San Francisco, CA, 2004, Abstract 96. 
20. Petra Study Team. Efficacy of three short course regimens of zidovudine and 
lamivudine in preventing early and late transmission of HIV-1 from mother to child in 
Tanzania, South Africa, and Uganda (Petra Study): a randomised, double blind placebo 
controlled trial. Lancet 2002;359:1178-1186. 
21. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. A 
multicenter randomized controlled trial of nevirapine versus a combination of zidovudine 
and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of 
human immunodeficiency virus type 1. J Infect Dis 2003; 187(5):725-35. 
22.Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum 
and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-
to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. 
Lancet 1999;354(9181):795-802. 
23. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M,  et al. Intrapartum 
and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-
to-child transmission of  HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 
012 randomised trial. Lancet. 2003;362: 859-68. 
24. Lockman S, Shapiro RL, Smeaton LM, Westor C,Thior I,Stevens L, et al. Response to 
antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 
2007;356:135-47. 
25. World Health Organization. Department of HIV/AIDS. Prevention of Mother-to-Child 
Transmission (PMTCT): Briefing Note. 2007. [cited 2009 Jun 30]. Available from: URL: 
http://motherchildnutrition.org/nutrition-protection-promotion/pdf/mcn-prevention-of-
mother-to-child-transmission.pdf 
26. Myburgh J. Here is the evidence of Mbeki’s denialisms. Politicsweb [Online]. [cited 
2007 Jun 30]. Available from: URL: 
http://www.politicsweb.co.za/politicsweb/view/politicsweb/en/page71619?oid=82478&sn=
Detail 
27. Treatment Action Campaign. A response to minister of health on mother to child 
transmission [Online]. [cited 2009 May 20]. Available from: URL: 
http://www.tac.org.za/community/node/2139 
 54 
28. National Department of Health. Policy and guidelines for the implementation of the 
PMTCT Programme [Online]. 2008. [cited 2009 May 30]. Available from: URL: 
http://www.doh.gov.za/docs/policy/pmtct.pdf 
29. Doherty TM, McCoy D, Donohue S. Health systems constraints to the optimal 
coverage of the prevention of mother-to-child HIV transmission programme in South 
Africa: lessons from the implementation of the national pilot programme. Afr Health Sci 
2005;5(3):213-8. 
30. Sherman GG, Jones SA, Coovadia AH, Urban MF, Bolton KD. PMTCT from research 
to reality--results from a routine service. S Afr Med J 2004;94(4):289-92. 
31. Rollins N, Little K, Mzolo S,Horwood C, Newell ML. Surveillance of mother-to-child 
transmission prevention programmes at immunization clinics: the case for universal 
screening. AIDS 2007;21(10):1341-7. 
32. Draper B, Abdullah F. A review of the prevention of mother-to-child transmission 
programme of the Western Cape provincial government, 2003 - 2004. S Afr Med J 
2008;98(6):431-4. 
33. Coetzee D, Hilderbrand K, Boulle A, Draper B, Abdullah F, Goemaere E. Effectiveness 
of the first district-wide programme for the prevention of mother to child transmission of 
HIV in South Africa. Bull World Health Organ 2005;83(7): 489-94. 
34. Geddes R, Knight S, Reid S, Giddy J, Esterhuizen T, Roberts C. Prevention of mother-
to-child transmission of HIV programme: low vertical transmission in KwaZulu-Natal, 
South Africa. S Afr Med J 2008;98:458-62. 
35. Schussler M. The Private Hospital Sector in South Africa. In: HASA Annals 2006. 
Johannesburg: Hospital Association of South Africa; 2006. 
36. Broomberg J, De Beer C, Price MR. The private health sector in South Africa -Current 
trends and future developments. S Afr Med J 1990;78(3):139-42. 
37. Regensberg L, Makiwane M. AfA clinical guidelines [online]. 7
th
 ed. Pineland: Aid for 
AIDS; 2009. [cited 2009 May 30]. Available from: URL: 
http://www.aidforaids.co.za/EX_Medscheme_VS07/Documents/AFA/Guidelines_book_Fi
nal.pdf 
38. Hlatshwayo N, Hislop MS, Cotton M, Maartens G, Regensberg LD. (2004) Mother to 
child HIV transmission prevention (MTCTP) in a managed care setting in South Africa - 
no role for short-term antiretroviral therapy (ART)? eJIAS 1:ThOrB1351. 
39. Kish L. Survey Sampling. New York: John Wiley and Sons; 1965.  
40. UN Integrated Regional Information Network. Southern Africa: A winning recipe for 
PMTCT but few follow it. 2009 [cited 2009 Jun 30]. Available from: 
URL:http://www.plusnews.org/Report.aspx?ReportId=74389 
41. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early 
antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 
359(21):2233-44. 
 
42. Ginsburg AS,  Hoblitzelle CW, Sripipatana TL, Wilfert CM. Provision of care 
following prevention of mother-to-child HIV transmission services in resource-limited 
settings. AIDS 2007;21:2529–2532. 
 55 
43. Minkoff H, Ahedia L, Watts H ,Greenblatt RM ,Schidmt J, Schneider M, et al. The 
relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet 
Gynecol 2001;184(6):1221-7. 
44. Hoque M, Hoque E, Kader SB. Audit of antenatal care in a rural district of KZN, South 
Africa. SA Fam Pract 2008;50(3):66. 
45. Benzies KM. Advanced maternal age: Are decisions about the timing of child- bearing 
a failure to understand the risks? CMAJ 2008;178(2):183-4. 
46. INDEPTH Network. INDEPTH Resource Kit for Demographic Surveillance Systems 
[online]. [cited 2009 May 30]. Available from: URL: http://www.indepth 
network.org/index.php?option=com_wrapper&Itemid=822 
47.Schuman P, Jones TB, Ohmit S, Laken MP.  Voluntary HIV Counselling and Testing of 
Pregnant Women -- An Assessment of Compliance With Michigan Public Health Statutes 
[Online]. Medscape General Medicine. 2004;6(2):52. [cited 2009 May 30]. Available from: 
URL: http://www.medscape.com/viewarticle/475007 
 
48. Rodriguez EJ, Spann C, Jamieson D, Lindsay M. Postoperative morbidity associated 
with cesarean delivery among human immunodeficiency virus-seropositive women. Am J 
Obstet Gynecol 2001;184(6):1108-11. 
49. Saving mothers: Report on Confidential Enquiries into Maternal Deaths in 
South Africa, 1998 [online]. Pretoria: Department of Health; [1999?] [cited 2009 May 30]. 
Available from: URL: http://www.doh.gov.za/docs/reports/mothers/chap09.html 
50. Royal College of Obstetricians and Gynaecologists (RCOG). Management of HIV in 
pregnancy[online]. London: Royal College of Obstetricians and Gynaecologists (RCOG); 
2004 [cited 2009 May 30]. Available from: URL: http://www.rcog.org.uk/files/rcog-
corp/uploaded-files/GT39ManagementHIVPregnancy2004.pdf 
51.Brocklehurst P, French R. The association between maternal HIV infection and 
perinatal outcome: a systematic review of the literature and meta-analysis. 
Br.J.Obstet.Gynaecol. 1998;105(8):836-48. 
52. Rollins NC, Coovadia HM, Bland RM, Coutsoudis A, Bennish ML, Patel D,et al. 
Pregnancy outcomes in HIV-infected and uninfected women in rural and urban South 
Africa. J Acquir Immune Defic Syndr 2007;44(3):321-8. 
53. World Health Organization, Department of Reproductive Health and Research. 
Maternal and newborn health: low birthweight: country, regional and global estimates 
[Online]. 2005 [cited 2009 May 30]. Available from: 
URL:https://www.who.int/reproductive-health/publications/low_birthweight/ 
54. Little Steps [online]. 2009 [cited 2009 May 30]. Available from: URL: 
http://www.littlesteps.co.za/ 
55. Cotter AM , Garcia A G, Duthely ML,Luke B, MJOSullivan. Is antiretroviral therapy 
during pregnancy associated with an increased risk of preterm delivery, low birth weight, 
or stillbirth? J Infect Dis 2006;193:1195-1201. 
56. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant 
HIV-infected women and the risk of premature delivery: a meta analysis. AIDS 
2007;21:607-15. 
 56 
57. World Health Organization. HIV and infant feeding [online]. 2009. [cited 2009 May 
30]. Available from: 
URL:http://www.who.int/child_adolescent_health/topics/prevention_care/child/nutrition/hi
vif/en/index.html 
58. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and 
the experience of the DREAM program in prevention of mother-to-child transmission of 
HIV. AIDS 2007;21 Suppl 4:S65-71. 
59. Becquet R, Bequet L, Ekouevi DK, Viho I, Sakarovitch C, Fassinou P, et al. Two-year 
morbidity-mortality and alternatives to prolonged breast-feeding among children born to 
HIV-infected mothers in Côte d'Ivoire. PLoS Med 2007;4(1):e17.  
60. HIV Clinical Resource Clinical guidelines: Pediatrics: HIV Testing and Diagnosis in 
Infants and Children [online]. [cited 2009 Jun 29]; Available from: URL: 
http://www.hivguidelines.org/GuidelineDocuments/p-test.pdf 
61. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, 
adolescents and adults [online]. [cited 2009 Jun 29]. Available from: URL: 
http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf 
62 . McNally LM, Jeena PM, Gajee K, Thula S, Sturm A, Cassol S, et al. Effect of age, 
polymicrobial disease, and Maternal HIV status on treatment responses and cause of severe 
pneumonia in South African children: a prospective descriptive study Impact of age, 
polymicrobial disease and maternal HIV status on response and aetiology of severe 
pneumonia in South African children. Lancet 2007;369:1440-1451. 
63. Jeena PM, Bobat B, Thula SA, Adhikari M. Children with Pneumocystis jiroveci 
pneumonia and acute hypoxaemic respiratory failure admitted to a PICU, Durban, South 
Africa [letter]. Arch Dis Child 2008;93(6):545.  
64.Coutsoudis A, Pillay K, Spooner E, Coovadia HM, Pembrey L, Newell ML. Routinely 
available cotrimoxazole prophylaxis and occurrence of respiratory and diarrhoeal 
morbidity in infants born to HIV-infected mothers in South Africa. S Afr Med J 
2005;95:339–345. 
65. Harambat J, Fassinou P, Becquet R, Touré P, Rouet F, Dabis F et al. 18-month 
occurrence of severe events among early diagnosed HIV-infected children before 
antiretroviral therapy in Abidjan, Côte d'Ivoire: a cohort study. BMC Public Health. 
2008;8:169. 
66. Kingston MA, Letham CJ, McQuillan O. Adherence to antiretroviral therapy in 
pregnancy. Int J STD AIDS 2007;18(11):787-9. 
 
 
 
